AI Meets the Lab

What the Life Sciences AI Push Means for Collaborations

The year 2026 has seen several major announcements in the Life Sciences Artificial Intelligence ("LS-AI") space land in quick succession. Amazon Web Services launched Amazon Bio Discovery, an end-to-end drug discovery platform; OpenAI unveiled GPT-Rosalind, a scientific reasoning partner for literature, database, and hypothesis work; and Biohub, backed by the Chan Zuckerberg Initiative, announced a $500 million commitment to generate large-scale, open-source biological datasets for model training and improvement. These developments follow Anthropic's launch of Claude Science, Claude for Life Sciences, and Claude for Healthcare, reflecting a growing demand for AI tools that can support regulated scientific and clinical workflows.

Taken together, these announcements point to technology companies and frontier AI labs engaging with multiple layers of the LS-AI stack, from cloud infrastructure and foundation models to biological datasets, scientific reasoning tools, and drug discovery platforms. They sit alongside earlier moves by Google DeepMind and Isomorphic Labs, whose pharma partnerships remain a prominent example of AI being deployed in drug discovery, as well as Microsoft's continued healthcare and life sciences AI activity through Microsoft Research and its broader cloud infrastructure ecosystem.

For pharma companies, these developments will likely mean internal R&D teams can move faster without being constrained by resources, including computational biology, programming, or analytics talent. The implications for dealmaking, commercialization success, and the global innovation map are significant—and the legal and operational questions they raise need particular attention now.

The Shifting Life Sciences AI Dealmaking Landscape: How Did We Get Here?

The acceleration of AI-enabled collaborations in drug discovery has not happened in a vacuum. The pharmaceutical industry has long been contending with productivity challenges—long development timelines, high attrition rates, and rising R&D costs—at the same time as a significant wave of patent expirations is expected to put over $200 billion in branded revenue at risk by the end of the decade. That combination has made drug pipeline replenishment a strategic priority, and LS-AI offers a potential route to compress early-stage timelines. The result has been a rapid scaling of cross-sector investment: industry estimates suggest that aggregate spending on AI drug discovery partnerships, acquisitions, and internal build-outs has exceeded $8.5 billion globally through 2025.

Partnerships have been the dominant and fastest-growing channel for capital deployment. Global pharma companies are making billion-dollar AI infrastructure investments with major technology and chip companies, and committing to multi-year research collaborations with universities to build AI-driven drug discovery capability. Technology companies and frontier AI labs are also investing heavily in their own platform development, building catalogs of biological AI models, agentic interfaces, and integrated laboratory networks that connect computational design directly to physical testing. LS-AI is treated as a core strategic vertical. As pharma companies increasingly access AI-driven discovery capabilities through cloud or AI infrastructure providers, negotiating postures are shifting, and the terms underpinning these collaborations take on new significance. 

What Makes or Breaks Life Sciences AI Collaborations 

As LS-AI becomes central to drug discovery workflows, the collaboration agreements governing them will need to account for a different set of dynamics. The commercial structures, data flows, and infrastructure dependencies involved raise questions that milestone and royalty frameworks in traditional R&D collaborations and co-development models were not designed to address. Below, we set out the key areas where such arrangements will need particular attention. 

• Commercial architecture. LS-AI collaborations now span a broad spectrum, from traditional co-development structures with milestones and royalties, to usage-based platform subscriptions linked to infrastructure access rather than therapeutic outcomes. Where a deal sits on that spectrum has significant implications for its key commercial and IP terms, making early alignment on the appropriate model important, particularly where a scoped pilot may evolve into a broader, multi-program relationship.
• Intellectual property allocation. Platform-based collaborations can blur the line between pre-existing platform IP and collaboration-specific outputs, making clear delineation of background and foreground IP essential. Inventorship allocation also requires attention, as major patent offices currently require a natural person as inventor, creating a structural tension where AI-generated candidates form the basis of patent filings. Incorrect inventorship designations can jeopardize patent validity and enforceability. Where the collaboration sits within a broader enterprise or cloud agreement, parties should confirm how any standard-form IP terms interact with bespoke collaboration provisions.
• Data ownership and model training rights. A central tension in these collaborations is how proprietary data interacts with the LS-AI provider's broader model training processes, including whether collaboration-generated data can be used to improve platform models more broadly, and whether data isolation can be achieved technically, contractually, or both. Ownership of experimental data and fine-tuned models, and the treatment of that data on termination or change of control, should be addressed explicitly.
• Confidentiality in multi-client platform environments. Where sensitive compound structures, unpublished target hypotheses, proprietary experimental results, and clinical data (even if de-identified) reside on infrastructure serving multiple clients, the question is not simply whether confidentiality obligations exist, but what technical and organizational measures ensure that one client's data cannot benefit another—even indirectly through platform-wide model improvements.
• Risk allocation and liability. Where a platform's predictions inform compound selection, dosing, or trial design, the parties should agree how responsibility for the use of those outputs will be allocated. This should reflect the role each party plays in validating and acting on them. Limitations of liability should be calibrated accordingly, recognizing that LS-AI providers are typically supplying enabling technology rather than assuming responsibility for therapeutic outcomes or corresponding regulatory obligations.
• Platform dependency, portability, and wind-down. Where discovery workflows and fine-tuned models reside on a single provider's infrastructure, data portability, model export rights, and transition assistance should be agreed upfront. This is particularly important for emerging biotechs whose core IP may be deeply integrated with a specific LS-AI provider's architecture, especially where unwinding may involve model retraining, data migration, and continuity of any regulatory submissions that depend on platform-generated data.
• Cross-border data flows. Global cloud and AI infrastructure providers may trigger cross-border data transfer obligations under regimes such as the EU General Data Protection Regulation ("GDPR") and China's data export regulations. Data governance provisions should address storage, processing locations, and the regulatory requirements of every relevant jurisdiction.
• Given the sensitivity of prepublication compound data, proprietary hypotheses, and clinical data (even if de-identified) held on LS-AI platforms, cybersecurity obligations should be addressed explicitly, including minimum security standards, breach notification mechanics, and liability for security failures. This is particularly important where the LS-AI provider serves multiple clients. For pharmaceutical companies subject to the EU NIS2 Directive, ensuring that suppliers and service providers comply with robust cybersecurity standards is now a legal requirement.
• Regulatory and compliance alignment. Where the LS-AI provider's primary regulatory remit is technology rather than life sciences, GxP compliance, audit rights, and model validation documentation should be addressed explicitly rather than assumed. The EU AI Act adds a further compliance dimension: transparency obligations, data governance requirements, and the general-purpose AI model provisions may all be relevant to LS-AI platforms operating in the European market.

Priorities for Stakeholders

These collaboration dynamics have an important international dimension, including the interplay between U.S.-centric LS-AI platforms, China's rapidly growing role in AI-enabled asset origination, and evolving global regulatory frameworks. 

Regulators globally are signaling a commitment to risk-based frameworks that support the use of AI in medicines development while protecting patient safety. In the United States, for example, the Food and Drug Administration ("FDA") has established a new Office of Innovation and Clinical Trial Modernization, including dedicated divisions for AI and real-world evidence analytics. In the EU, reforms of pharmaceutical and clinical trial frameworks are under way, while the United Kingdom recently overhauled its clinical trials regulations and is preparing updates to its medical devices regime. While early-stage discovery work may remain largely outside medicines regulation, regulatory expectations may increase as AI outputs move downstream into trial design, clinical data analysis, and regulatory submissions. For collaboration partners, this means requirements for validation, data provenance, and documentation should be built into agreements from the outset.

While no fully AI-designed drug has yet been approved, the scale of capital now flowing into this space means that the commercial, contractual, and regulatory questions are live today. the landscape continues to evolve, stakeholders should ensure that the agreements underpinning these collaborations are built for the dynamics they actually involve, and that internal governance, risk frameworks, and negotiating playbooks reflect the unique characteristics of AI-enabled drug discovery collaborations.